The Latest Cardiac and Vascular News
LIVERMORE, Calif., April 27, 2026 /PRNewswire/ — Advanced Bifurcation Systems Inc. (“ABS”), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, today announced that it has recently acquired all assets of Svelte Medical Systems, Inc. (“Svelte”). The acquired…
CAMBRIDGE, England–(BUSINESS WIRE)–PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease (CVD), today announced it has raised $5 million. The oversubscribed financing round was funded entirely by the Company’s existing investor base. The investment will support the continued build-out of PlaqueTec’s proprietary cardiovascular data lake, BioCarta, a growing repository of unique intracoronary proteomic and clinical data. B
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to
SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic commercialization collaboration with Johnson & Johnson to expand access to Viz.ai’s Subdural Hemorrhage software solution across hospitals in the United States for automated detection, labeling and quantification of subdural collections. By integrating the Viz Subdural solution into its neurovascular offerings, the company aims to support hospital
Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging System Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging System
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026.
CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks,…
NEW YORK, April 20, 2026 /PRNewswire/ — Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by…
Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and […]
